Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overexpression of RAD51 occurs in aggressive prostatic cancer.
Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators; Eeles R, Foster CS. Mitra A, et al. Among authors: barbachano y. Histopathology. 2009 Dec;55(6):696-704. doi: 10.1111/j.1365-2559.2009.03448.x. Histopathology. 2009. PMID: 20002770 Free PMC article.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L; IMPACT Study Collaborators; Easton DF, Eeles RA. Mitra AV, et al. Among authors: barbachano y. BJU Int. 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. BJU Int. 2011. PMID: 20840664 Free PMC article.
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology. Edwards SM, et al. Among authors: barbachano y. Br J Cancer. 2010 Sep 7;103(6):918-24. doi: 10.1038/sj.bjc.6605822. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736950 Free PMC article.
The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
Bancroft EK, Locke I, Ardern-Jones A, D'Mello L, McReynolds K, Lennard F, Barbachano Y, Barwell J, Walker L, Mitchell G, Dorkins H, Cummings C, Paterson J, Kote-Jarai Z, Mitra A, Jhavar S, Thomas S, Houlston R, Shanley S, Eeles RA. Bancroft EK, et al. Among authors: barbachano y. J Med Genet. 2010 Jul;47(7):486-91. doi: 10.1136/jmg.2009.072728. Epub 2010 May 14. J Med Genet. 2010. PMID: 20472659
Outcome of early detection and radiotherapy for occult spinal cord compression.
Venkitaraman R, Barbachano Y, Dearnaley DP, Parker CC, Khoo V, Huddart RA, Eeles R, Horwich A, Sohaib SA. Venkitaraman R, et al. Among authors: barbachano y. Radiother Oncol. 2007 Dec;85(3):469-72. doi: 10.1016/j.radonc.2007.10.043. Epub 2007 Nov 26. Radiother Oncol. 2007. PMID: 18036691
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I. Dewdney A, et al. Among authors: barbachano y. J Clin Oncol. 2012 May 10;30(14):1620-7. doi: 10.1200/JCO.2011.39.6036. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473163 Clinical Trial.
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Waddell T, et al. Among authors: barbachano y. Lancet Oncol. 2013 May;14(6):481-9. doi: 10.1016/S1470-2045(13)70096-2. Epub 2013 Apr 15. Lancet Oncol. 2013. PMID: 23594787 Free PMC article. Clinical Trial.
54 results